What next after Horomonotheapy in Cancer prostate?. | [Journal of College of Physicians and Surgeons--Pakistan : JCPSP • 2003]

Author(s):

1. Tariq Pervez: Department of Oncology, King Fahad Hospital, Al-Madina Al-Munawar, KSA

2. Imtiaz Ibraheim: Department of Oncology, King Fahad Hospital, Al-Madina Al-Munawar, KSA

3. Hamza Al-Sisi: Department of Oncology, King Fahad Hospital, Al-Mdina Al-Munawar, KSA

Abstract:

Treatment of hormone-resistance cancer prostate (HRCP) is undergoing evolution. Chemotherapy is now increasingly being utilized. The steps involved in the hormone management and the role for chemotherapy in the current time are being discussed. Hormonal management is carried out at different stages of hormonal sensitivity by sequential hormonal use. Once hormonal resistance is established, the combination of mitoxantrone and prednisone become a standard chemotherapeutic approach. New agents, such as docetaxel, are being tested in phase-III trials against mitoxantrone plus prednisone. HRCP is now regarded as a chemotherapy-sensitive tumor. The goals of chemotherapy in HRCP are to decrease PSA level and improve quality of life. New agents and combinations are needed to improve survival to meet this end.

Page(s): 606-610

DOI: DOI not available

Published: Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 13, Issue: 10, Year: 2003

Keywords:

Keywords are not available for this article.

References:

References are not available for this document.

Citations

Citations are not available for this document.

Citations

Downloads

Views